After retreating 26% in Q4, the Canadian Cannabis LP Index extended its losing streak to seven months as it fell again in January, declining 9.5% to 176.42:
The index, which fell 29.2% in 2021 to end at 194.95, has declined 49.4% over the past year:
It remains substantially below the all-time closing high of 1314.33 in September 2018, just ahead of Canadian adult-use legalization. In March 2020, it posted a new multi-year closing low of 196.10, a level that had not been seen since late 2016, and it closed 10.0% below that level this month:
The Canadian Cannabis LP Index, which is rebalanced monthly, included 24 qualifying publicly traded licensed producers that traded in Canada at the end of December, with equal weighting for each stock. Each of the members was also included in a sub-index, with 4 in the Canadian Cannabis LP Tier 1 Index, 8 in the Canadian Cannabis LP Tier 2 Index and 12 in the Canadian Cannabis LP Tier 3 Index during the month. At the end of November 2021, we raised the minimum for Tier 1 from C$25 million to C$30 million, for Tier 2 from C$5 million to C$7.5 million and for Tier 3 to C$2.5 million from zero. This was the first change since June 2020, when we required companies to have a price of at least C$0.20 unless they are generating at least C$2.5 million quarterly from their cannabis production operation. Previously, we required revenue in excess of C$1 million for stocks trading below C$0.20. There are currently more than two dozen publicly traded LPs that fail to qualify.
Tier 1, which included the LPs that are generating cannabis-related sales of at least C$30 million per quarter, fell 15.9% to 264.34 in January. Tier 1 dropped 17.7% in 2021 when it ended at 314.28. We have increased the minimum revenue required to be included over time. In November 2021, we raised it from C$25 million. At the beginning of 2021, we raised it from C$20 million. During 2019 and the first half of 2020, companies needed to generate revenue in excess of C$10 million for inclusion. In 2018, we used C$4 million as the hurdle.
Among these largest LPs by revenue, Aurora Cannabis was the worst performer, falling 23%. The best performing company was Canopy Growth, which fell 7.4%.
Tier 2, which included the LPs that generate cannabis-related quarterly sales between C$7.5 million and C$30 million, fell 11.5% to 236.53. In 2021, it lost 17.1%, closing at 267.36. Prior to December 2021, companies needed revenue in excess of C$5 million to qualify for inclusion. Prior to July 2020, companies needed revenue in excess of C$2.5 million to be included in this tier.
This group included Aleafia Health (TSX: AH) (OTC: ALEAF), Auxly (TSX: XLY) (OTC: CBWTF), Cronos Group (TSX: CRON) (NASDAQ: CRON), Decibel Cannabis (TSXV: DB) (OTC: DBCCF), Entourage Health (TSXV: ENTG) (OTC: ETRGF), Indiva (TSXV: NDVA) (OTC: NDVAF) Organigram (TSX: OGI) (NASDAQ: OGI) and Valens Company (TSX: VLNS) (NASDAQ: VLNS).
Among these companies, Aleafia saw the largest decline, 22%, while Entourage had the largest gain, 6%.
Tier 3, which included the 12 qualifying LPs that generate cannabis-related quarterly sales of C$2.5-C$7.5 million, fell 6.0% as it closed at 44.56. It ended at 47.42 in 2021, declining 19.9%. The worst performance among this group was from IM Cannabis (CSE: IMCC) (NASDAQ: IMCC), which dropped 41%. The best performer was Lifeist Wellness (TSXV: LFST) (OTC: NXTTF), which rose 20%.
The returns for the overall sector varied greatly, with 3 names posting double-digit gains and 6 declining by more than 20%. The entire group posted a median return of -9.2%:
For February, the overall index will continue to have 24 constituents. Organigram will now be included in Tier 1 rather than Tier 2.
In the next monthly review, we will summarize the performance for February and discuss any additions or deletions. Be sure to bookmark the pages to stay current on LP stock price movements within the day or from day-to-day.